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Abstract
Site-directed mutations of tyrosine (Y) to phenylalanine (F) on the surface of adeno-associated viral (AAV)
capsids have been reported as a simple method to greatly enhance gene transfer in vitro and in vivo. To determine
whether the Y-to-F mutation could also enhance AAV8 and AAV9 gene transfer in skeletal muscle and heart to
facilitate muscular dystrophy gene therapy, we investigated four capsid mutants of AAV8 (Y447F or Y733F) and
AAV9 (Y446F or Y731F). The mutants and their wild-type control AAV8 and AAV9 capsids were used to
package reporter genes (luciferase or b-galactosidase) resulting in similar vector yields. To evaluate gene de-
livery efficiencies, especially in muscle and heart, the vectors were compared side by side in a series of exper-
iments in vivo in two different strains of mice, the outbred ICR and the inbred C57BL/6. Because AAV8 and
AAV9 are among the most effective in systemic gene delivery, we first examined the mutant and wild-type
vectors in neonatal mice by intraperitoneal injection, or in adult mice by intravenous injection. To our surprise,
no statistically significant differences in transgene expression were observed between the mutant and wild-type
vectors, regardless of the reporter genes, vector doses, and the ages and strains of mice used. In addition,
quantitative analyses of vector DNA copy number in various tissues from mice treated with mutant and wild-
type vectors also showed similar results. Finally, direct intramuscular injection of the above-described vectors
with the luciferase gene into the hind limb muscles revealed the same levels of gene expression between mutant
and wild-type vectors. Our results thus demonstrate that a single mutation of Y447F or Y733F on capsids of
AAV8, and of Y446F or Y731F on AAV9, is insufficient to enhance gene delivery to the skeletal muscle and heart.
Introduction
Adeno-associated viral (AAV) vectors have been in-creasingly used as a vector of choice for in vivo gene
delivery and gene therapy for many genetic diseases, such as
hemophilia B (Manno et al., 2003; Nathwani et al., 2011), Le-
ber’s congenital amaurosis (Hauswirth et al., 2008; Maguire
et al., 2008, 2009), Parkinson’s disease (Kaplitt et al., 2007), and
hereditary muscular dystrophies (Wang et al., 2000; Harper
et al., 2002; Mendell et al., 2009, 2010). The lack of pathoge-
nicity of the wild-type virus, the broad tissue tropism, as well
as the persistence of transgene expression have bolstered the
potential of AAVs as a class of safe and effective delivery
vehicles for gene therapy applications (Daya and Berns,
2008). AAV2 was the first AAV serotype that was made into
vectors for gene transfer in preclinical and clinical applica-
tions (Samulski et al., 1982; Xiao et al., 1999; Flotte et al., 2003;
Brantly et al., 2009). Despite some clinical success (Maguire
et al., 2008, 2009), AAV2 is limited by the relatively low effi-
ciency of gene transfer, slower onset of gene expression, and
higher prevalence of preexisting immunity in human popu-
lations (Gao et al., 2005). To overcome such drawbacks, many
investigators have successfully explored either naturally oc-
curring (Gao et al., 2002) or genetically engineered and mod-
ified (Schaffer and Maheshri, 2004; Muzyczka and
Warrington, 2005; Li et al., 2008; Yang et al., 2009) novel AAV
capsids, which are the major determinants of tropism and
transduction efficiency. To date more than 11 AAV serotypes
(Wu et al., 2006) and more than 100 naturally occurring pri-
mate AAV variants have been reported (Gao et al., 2005). The
efficiency of AAV transduction depends on the efficiency at
each step of AAV infection: receptor binding, cell entry, in-
tracellular trafficking, uncoating, second-stranded synthesis,
vector genome stabilization, and so on (Daya and Berns,
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2008). Among them, intracellular trafficking (Hauck et al.,
2004) and second-strand synthesis (Ferrari et al., 1996) have
been identified as the rate-limiting steps (Ding et al., 2005;
Keiser et al., 2010). Some serotypes of AAV are naturally more
effective than others in this process to escape the endosomes
and evade proteasomes in order to finally reach inside the cell
nucleus.
One report described a new concept and simple method
to enhance AAV particle intracellular trafficking by ablat-
ing the surface-exposed tyrosine residues, which have a
hydroxyl group as a substrate for phosphorylation and
subsequent ubiquitination (Zhong et al., 2008b). It was hy-
pothesized that mutations of the tyrosine to phenylalanine,
which lacks the hydroxyl group, should allow the vectors to
evade phosphorylation and subsequent ubiquitination and
proteasome-mediated degradation. Indeed, mutations of the
surface-exposed tyrosine in AAV2 vectors have been re-
ported to dramatically enhance transduction efficiency both
in vitro and in vivo (Zhong et al., 2008a,b; Kauss et al., 2011; Li
et al., 2011; Markusic et al., 2011; Petrs-Silva et al., 2011).
Additional studies have shown variable degrees of en-
hancement of gene transfer and expression in other AAV
serotypes (Petrs-Silva et al., 2009; Qiao et al., 2010; Dalkara
et al., 2011; Pang et al., 2011).
Our laboratory has long been interested in gene therapy
for muscular dystrophy and cardiomyopathy. Thus far,
AAV8 and AAV9 have been identified as the most efficient
vectors in crossing the blood vessel barrier to achieve sys-
temic gene transfer in both skeletal and cardiac muscle
(Wang et al., 2005; Inagaki et al., 2006; Kornegay et al., 2010).
In this study, we wished to investigate whether tyrosine
mutation could enhance the gene transfer efficiencies of
AAV8 and AAV9 to the muscle and heart of mice after
systemic or intramuscular administration of the vectors. The
improved AAV8 and AAV9 vectors should allow for im-
proved transduction efficiency at a lower vector dose re-
quirement and better safety profile. To this end, we have
carried out a series of experiments in mice to compare the
transduction efficiency of two AAV8 mutants (Y447F or
Y733F) and two AAV9 mutants (Y446F or Y731F) with the
original wild-type AAV8 and AAV9 counterpart vectors. To
our surprise, we did not observe any statistically significant
enhancement of transgene expression by mutation of tyro-
sine to phenylalanine (Y to F) at amino acid residue 447 or
733 on AAV8 and at amino acid residue 446 or 731 on AAV9
capsids. Potential reasons for the negative findings and a
dramatic discrepancy between a previous report using




The AAV8 and AAV9 packaging plasmids containing the
original (also termed wild-type) capsid gene were obtained
from the J. Wilson laboratory of the University of Pennsyl-
vania (Philadelphia, PA) (Bish et al., 2008). The mutant AAV8
and AAV9 packaging plasmids containing the tyrosine (Y)-
to-phenylalanine (F) mutations were provided by A. Sri-
vastava of the University of Florida (Gainesville, FL) (Zhong
et al., 2008b). The AAV reporter vector plasmids pAAV-
CMV-Luc and pAAV-CMV-LacZ (with nuclear localization
signal, nls) have been described elsewhere (Qiao et al., 2011).
Recombinant AAV vectors were generated by the triple-
plasmid transfection method (Xiao et al., 1998). Viral vector
stocks were purified by polyethylene glycol (PEG) precipi-
tation followed by double CsCl gradient purification (Ayuso
et al., 2010). After three changes of dialysis in virus dialysis
buffer (1 · phosphate-buffered saline [PBS], 2% mannitol,
6 mM MgCl2) at room temperature for 6 to 8 hr or at 4C
overnight, vector genome copy titers were determined by
DNA dot blot and confirmed by quantitative PCR.
In vivo gene transfer
All animal experiments were approved by the institutional
animal care and use committee. For the luciferase intramus-
cular injection and neonatal delivery studies, 6- to 8-week-
old male ICR mice were purchased from Taconic (Hudson,
NY). An amount equivalent to 3 · 1010 VG/injection was
injected directly into the tibialis anterior (TA) and gastroc-
nemius (GAS) muscles. For neonatal delivery, different doses
of AAV vector (1 · 1010 VG/pup for the low-dose group, and
1 · 1011 VG/pup for the high-dose group) were introduced
into 3-day-old ICR pups via intraperitoneal injection. For
systemic delivery, 3 · 1011 VG total was delivered via tail
vein injection into 6- to 8-week-old C57BL/6 (BL6) mice,
which were purchase from Jackson Laboratory (Bar Harbor,
ME). All mice were killed 3 to 6 weeks posttreatment. There
were three mice in each group for all previously mentioned
studies.
Luciferase activity assay
Tissues (25–100 mg) were lysed and homogenized in luci-
ferase lysis buffer (0.05% Triton X-100, 0.1 M Tris-HCl [pH
7.8], 2 mM EDTA) in the presence of proteinase inhibitors
(cat. no. p2714; Sigma-Aldrich, St. Louis, MO). The homog-
enized lysate were extensively vortexed, and spun down at
4C for 2 min. The supernatant were used for luciferase ac-
tivity analysis. The analysis was performed according to a
previously described protocol (Yu et al., 2009), and a luci-
ferase assay kit (cat. no. E1501) was purchased from Pro-
mega (Madison, WI).
Genome copy determination
Total DNA was extracted with a kit (DNeasy blood and
tissue kit, cat. no. 69506; Qiagen, Valencia, CA). Vector copy
number was determined with a 7300 real-time PCR system
(Applied Biosystems, Foster City, CA). TaqMan assays for
endogenous control of the glucagon gene were developed to
normalize vector copy numbers. The sequences for mouse
glucagon primers and probes were as follows: Glucagon-
real-F (mouse), AAG GGA CCT TTA CCA GTG ATG TG;
Glucagon-real-R (mouse), ACT TAC TCT CGC CTT CCT
CGG; TaqMan mouse glucagon probe, FAM-cag caa agg aat
tca-MGB. For all the AAV vectors, primers and probes were
designed on the common bovine growth hormone (BGH)
poly(A) sequence. Their sequences were as follows: BGH-F,
AGC CTC GAC TGT GCC TTCTA; BGH-R, ATG CGA TGC
AAT TTC CTCAT; BGH probe, FAM-TGC CAG CCA TCT
GTTG. The copy number of delivered vector in a specific
tissue per diploid cell was calculated as (vector copy number/
endogenous control) · 2.
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X-Gal staining for expression of LacZ and LacZ
activity analysis
For 5-bromo-4-chloro-3-indolyl-b-d-galactoside (X-Gal)
staining, the cryo-thin-section slides were air-dried and fixed
in X-Gal fixative buffer containing 2% formaldehyde and
0.2% glutaraldehyde in PBS. After washing with PBS, the
slides were subjected to X-Gal staining buffer at 37C over-
night. The X-Gal staining buffer consisted of 0.1 M phos-
phate buffer (pH 7.3) supplemented with 2 mM MgCl2, 5 mM
potassium ferrocyanide (cat. no. P-9287; Sigma-Aldrich)
and 5 mM potassium ferricyanide (cat. no. P-8131; Sigma-
Aldrich). Before use, X-Gal was added at a final concentra-
tion of 1 mg/ml (Qiao et al., 2002).
To quantitate LacZ expression, we used a Galacto-Light
Plus kit (cat. no. T1007; Applied Biosystems). The manufac-
turer’s protocol was strictly followed. The relative units of
LacZ activity were normalized by total protein concentra-
tion, which was assessed with a Pierce BCA protein assay kit
(cat. no. 23227; Pierce Biotechnology, Rockford, IL).
Statistical analysis
Data are presented as means – standard deviation. Com-
parison among groups was performed by one-way analysis
of variance (ANOVA) followed by Dunnett post hoc test
(compare all columns vs. control group). p < 0.05 was con-
sidered statistically significant.
Results
Systemic gene delivery in neonatal ICR mice
by intraperitoneal injection
Different genetic backgrounds of mice may occasionally
lead to different outcomes of AAV gene transfer. We there-
fore evaluated the Y to F-mutated AAV8 and AAV9 vectors
in outbred ICR mice as well as in inbred C57BL/6 mice. We
started with neonatal and adult ICR mice, using two reporter
genes: firefly luciferase (Luc) and b-galactosidase (LacZ). The
Luc reporter provides a broad liner range for quantita-
tive analysis, whereas the LacZ reporter can be used to visu-
alize the individual cells in tissues and also to quantitate
b-galactosidase activities. Both reporter genes were controlled
by the strong ubiquitous cytomegalovirus (CMV) promoter.
The mutant AAV8 (Y447F or Y733F) and AAV9 (Y446F or
Y731F) packaging plasmids were generously provided by A.
Srivastava (Zhong et al., 2008b). The mutations were indepen-
dently confirmed by DNA sequencing. There was no difference
in viral vector yields among all four Y-to-F mutants and their
wild-type AAV8 and AAV9 controls, suggesting that the point
mutations did not compromise the vector packaging capacity.
FIG. 1. Comparison of Y-to-F mutants and wild-type AAV8 and AAV9 vectors encoding luciferase by systemic delivery in
neonatal ICR mice. The mutants and wild-type Luc vectors controlled by the CMV promoter were injected intraperitoneally
into 3-day-old ICR mice (low dose, 1 · 1010 VG/mouse; high dose, 1 · 1011 VG/mouse). The mice were killed 6 weeks later for
analyses of luciferase activities in samples from the heart, tibialis anterior (TA) and triceps muscles, and vector DNA copy
numbers in the heart. (a) Luciferase activities of mice treated with mutant and wild-type AAV8-Luc vectors ( p > 0.05 by one-
way ANOVA, n = 3). RLU, relative light units. (b) Luciferase activities of mice treated with mutant and wild-type AAV9-Luc
vectors ( p > 0.05 by one-way ANOVA, n = 3). (c) DNA copy numbers in heart tissues from mice treated with mutant and wild-
type AAV8-Luc vectors ( p > 0.05, one-way ANOVA followed by Dunnett post hoc test, n = 3). (d) DNA copy numbers in heart
tissues from mice treated with mutant and wild-type AAV9-Luc vectors ( p > 0.05 by one-way ANOVA, n = 3).
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We first evaluated the four mutants and wild-type AAV8
and AAV9 vectors in 3-day-old neonatal ICR mice by intra-
peritoneal injection, which is the most convenient approach
to achieve systemic delivery to the skeletal muscle and heart
with minimal vector dose requirement yet robust gene
transfer efficiency (Wang et al., 2005, 2009). Two vector doses
were used (low dose, 1 · 1010 VG/mouse; high dose, 1 · 1011
VG/mouse) for all six AAV vectors (AAV8-Luc, AAV8-
Y447F-Luc, AAV8-Y733F-Luc, AAV9-Luc, AAV9-Y446F-Luc,
and AAV9-Y731F-Luc). Six weeks postinjection, the mice
were killed and various muscle tissues and major organs
were carefully dissected and immediately snap-frozen. Half
of the muscle tissue samples were used for the luciferase
activity assay and the other half for DNA extraction and
quantitative analysis of vector copy numbers. To our sur-
prise, the luciferase activity assay revealed no significant
enhancement for any of the Y-to-F mutants when compared
with their parental wild-type AAV8 and AAV9 controls (Fig.
1a and b). Subsequently, quantitative real-time PCR analyses
were performed to evaluate vector DNA copy numbers in
heart tissue, because both AAV8 and AAV9, especially AAV9,
are effective in cardiac gene transfer by systemic delivery.
Again, no significant and consistent differences in vector DNA
copy numbers between mutant and wild-type vectors were
observed (Fig. 1c and d) ( p > 0.05, one-way ANOVA followed
by Dunnett post hoc test). The vector copy numbers are in
general agreement with transgene expression levels, suggest-
ing consistent vector binding and intracellular trafficking
among the mutant and wild-type vectors.
In addition to luciferase, we also used the LacZ reporter to
evaluate the mutant AAV8 and AAV9 vectors in neonatal
ICR mice. Six AAV vectors (AAV8-LacZ, AAV8-Y447F-LacZ,
AAV8-Y733F-LacZ, AAV9-LacZ, AAV9-Y446F-LacZ, and
AAV9-Y731F-LacZ) were injected intraperitoneally into 3-
day-old ICR pups at a dose of 5 · 1010 VG/mouse. The mice
were killed 6 weeks after treatment. No significant en-
hancement of LacZ expression by mutant AAV8 and AAV9
vectors over their wild-type controls was observed in , heart,
liver, or muscles (Fig. 2a and b). These results are in agree-
ment with the findings in the luciferase experiments.
Systemic gene delivery in adult ICR mice
by intravenous injection
We next investigated systemic delivery in adult ICR mice
to further evaluate the performance of the mutant AAV8 and
AAV9 vectors. The same six AAV-LacZ vectors used in the
neonatal experiments were administered in 6- to 8-week-old
ICR adult mice by tail vein injection at a vector dose of 3 · 1011
VG/mouse. Three weeks postinjection, the mice were killed
and tissues were collected and analyzed. X-Gal staining of
cryo-thin sections of the heart, liver, and muscles did not reveal
any significant difference in LacZ expression between the
mutant and wild-type vectors (Fig. 3a). Consistently, quanti-
tative analysis of LacZ enzyme activities in the tissue homog-
enates revealed no statistically significant differences either
between those vectors ( p > 0.05, one-way ANOVA) (Fig. 3b).
Systemic gene delivery in adult C57BL/6 mice
by intravenous injection
In an earlier report C57BL/6 mice were used to examine
the same Y-to-F mutants of AAV9 capsids used in our
studies. However, highly dramatic enhancement of gene
delivery by AAV9-Y731F was reported (Zhang et al., 2009).
For consistency we also used C57BL/6 mice in our study to
rule out the possibility that different mouse strains gave rise
to different outcomes. Similar to the experiments done in
adult ICR mice, the same six AAV-CMV-Luc vectors of both
mutant and wild-type AAV8 and AAV9 were injected into 6-
to 8-week-old C57BL/6 mice via the tail vein, at a vector
dose of 3 · 1011 VG/mouse. In addition, AAV-CMV-LacZ
vectors of mutant and wild-type AAV9 were also injected
into 6- to 8-week-old C57BL/6 mice via the tail vein, but in
two dose groups (1 · 1011 and 3 · 1011 VG/mouse). The mice
were killed 3 weeks postinjection. Once again, we did not
observe any significant difference in either luciferase expres-
sion ( p > 0.05, one-way ANOVA; Fig. 4) or LacZ expression
( p > 0.05, one-way ANOVA; Fig. 5a and b) between mutant
and wild-type AAV8 and AAV9 vectors. In addition, quan-
titative real-time PCR analysis of the LacZ vector DNA iso-
lated from tissues did not reveal statistically significant
difference in DNA copy numbers between mutant and wild-
type vectors ( p > 0.05, one-way ANOVA; Fig. 5c and d). These
results strongly demonstrated that the strains of mice did not
make appreciable differences in the in vivo examination of the
mutant and wild-type AAV8 and AAV9 vectors.
Local intramuscular injection in ICR mice
Previously, we have observed that two tyrosine mutants,
AAV6-Y445F and AAV6-Y731F, achieved enhanced gene
transfer and expression of luciferase reporter gene by a
few fold over their parental wild-type AAV6 vectors after
FIG. 2. Comparison of Y-to-F mutants and wild-type
AAV8 and AAV9 vectors encoding LacZ reporter by sys-
temic delivery into neonatal ICR mice. Mutants and wild-
type LacZ-vectors controlled by the CMV promoter were
injected intraperitoneally into 3-day-old ICR mice at a dose
of 5 · 1010 VG/mouse. The mice were killed 6 weeks later for
analysis of b-galactosidase activities in samples from heart,
liver, and tibialis anterior (TA) and gastrocnemius (GAS)
muscles ( p > 0.05 by one-way ANOVA, n = 3).
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intramuscular injection in the ICR mice (Qiao et al., 2010).
The enhancement was more appreciable at low vector doses.
To determine whether similar enhancement could be
achieved with the mutant AAV8 and AAV9 vectors, we
carried out local intramuscular injection that delivered viral
particles directly to the muscle tissues without the involve-
ment of a blood vessel barrier. Low vector doses were used
to avoid dose saturation. For each mouse, two muscles of the
left hind leg, the tibialis anterior (TA) and gastrocnemius
(GAS), were injected with 3 · 1010 VG/site in a 50-ll vector
volume. Three weeks postinjection, the muscles were col-
lected and subjected to luciferase activity assay. As shown in
Fig. 6, we could not observe meaningful enhancement of
transgene expression in any mouse in the Y-to-F mutant
group. It appeared to have a trend of enhanced gene ex-
pression in AAV9-Y446F mutant vector-treated TA muscles,
but the difference did not reach statistical significance (AAV9
comparison, p = 0.109; AAV8 comparison, p = 0.6888 by one-
way ANOVA). These results suggest that the surface-
exposed tyrosine mutation in AAV8 and AAV9 capsids
could not significantly enhance their gene transfer efficiency
in skeletal muscle tissues in mice.
Discussion
Muscular dystrophy gene therapy requires therapeutic
gene transfer to most of the striated muscle cells in a body-
wide manner to achieve desirable efficacies in patients.
Muscle is the largest organ in the body and its demand for
gene therapy vector is also the highest. For systemic gene
FIG. 3. Comparison of Y-to-F mutants and wild-type AAV9 vectors encoding LacZ reporter by systemic delivery in adult
ICR mice. The mutants and wild-type LacZ vectors controlled by the CMV promoter were injected via the tail vein into 6- to
8-week-old ICR mice at a dose of 3 · 1011 VG/mouse. The mice were killed 3 weeks postinjection. (a) Photographs of X-Gal
staining of representative tissues. Note that the LacZ vectors contained a nucleus localization signal (nls) and show nuclear
staining. TA, tibialis anterior; Gas, gastrocnemius. (b) Quantitation of LacZ expression by b-galactosidase activity assay
( p > 0.05 by one-way ANOVA, n = 3).
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delivery, AAV viral particles must cross the tight endothelial
barrier before reaching the surface receptors on muscle cells.
This places the bar even higher for AAV vectors to overcome.
Because high vector doses are often required for muscle
disease gene therapy in large animals (Kornegay et al., 2010)
and eventually in human patients, improvement in every
step of the gene transfer process counts. The tyrosine-to-
phenylalanine mutation was intended to overcome one of
the rate-limiting steps in AAV infection, that is, intracellular
trafficking. The design and principle behind the strategy is to
reduce ubiquitination sites on the viral particles to minimize
degradation, so that more of them can survive and emerge
out of the trafficking pathway and enter the nucleus for
transgene expression. AAV2 was the first serotype examined
by this new method. Ablation of surface-exposed tyrosines
dramatically enhanced gene transfer and expression, re-
ported as more than 10-fold and up to 30-fold in some in vitro
and in vivo experiments involving tissues such as the eye,
liver, and hematopoietic cells (Zhong et al., 2008a,b; Kauss
et al., 2011; Li et al., 2011; Markusic et al., 2011; Petrs-Silva
et al., 2011). The Y-to-F mutants of other serotypes, such as
AAV8 and AAV9, have also been reported to variably in-
crease gene expression in the eye and brain (Petrs-Silva et al.,
2009; Dalkara et al., 2011; Pang et al., 2011). AAV6 mutants
also significantly enhanced gene expression in skeletal
muscle by direct intramuscular injection, but not by systemic
routes in either neonatal or adult mice. Mutant AAV6-Y445F
was more effective than AAV6-Y731F. The enhancement ef-
fects varied in different muscle groups. For example, tibialis
anterior muscle was more effectively treated than gastroc-
nemius muscle (Qiao et al., 2010). Because AAV8 and AAV9
FIG. 4. Comparison of Y-to-F mutants and wild-type
AAV8 and AAV9 vectors encoding luciferase in adult
C57BL/6 mice. The mutant and wild-type Luc vectors con-
trolled by the CMV promoter were injected via the tail vein
into 6- to 8-week-old C57BL/6 mice at a dose of 3 · 1011 VG/
mouse. The mice were killed 3 weeks postinjection ( p > 0.05
for all comparisons by one-way ANOVA, n = 3). (a) Lucifer-
ase expression of wild-type and mutant AAV8 vectors.
(b) Luciferase expression of wild-type and mutant AAV9
vectors.
FIG. 5. Comparison of Y-to-F mutants and wild-type AAV9 vectors encoding LacZ in adult C57BL/6 mice. The mutant and
wild-type LacZ vectors encoding nuclear LacZ were injected via the tail vein into 6- to 8-week-old C57BL/6 mice at two
vector doses (low titer, 1 · 1011 VG/mouse; high titer, 3 · 1011 VG/mouse). The mice were killed 3 weeks postinjection
( p > 0.05 for all comparisons between mutant and wild-type vectors by one-way ANOVA, n = 3). (a) Quantitation of LacZ
expression by b-galactosidase activity assay in the low-titer group. (b) Quantitation of LacZ expression in the high-titer
group. (c) Vector DNA copy numbers in heart tissue. (d) Vector DNA copy numbers in liver tissue.
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mutant vectors are among the most effective vectors for
muscle and heart gene transfer by systemic administration,
we tested four mutants of AAV8 and AAV9, two for each, to
determine whether the Y-to-F mutations could also greatly
enhance systemic gene delivery to the muscle and heart. As
described in Results, however, we did not find any statisti-
cally significant improvement in multiple experiments with
two reporter genes at different doses, two strains of mice,
and two different age groups (neonate and adult) during
vector administration. In addition, we did not observe any
enhancement effect in cultured U87 cells in vitro using the
tyrosine mutant AAV8 and AAV9 vectors with both LacZ
and Luc reporter genes (Supplementary Fig. S1; supple-
mentary data are available online at www.liebertonline
.com/hgtb). The negative findings are somewhat disap-
pointing, but nonetheless informative and useful.
There could be a number of potential reasons and plau-
sible explanations for the negative findings. First of all, the
basis of the Y-to-F mutation is to enhance AAV particle in-
tracellular trafficking. If a certain serotype of AAV in a given
tissue/cell type is already efficient in this process, one would
not expect significant improvement after all. For example,
AAV8 is one of the most robust vectors for liver gene de-
livery. AAV8 is also found effective in intracellular traffick-
ing and uncoating. On the other hand, AAV2 is ineffective in
the above-cited processes in the liver and therefore poor in
hepatic gene transfer, despite the fact that its receptor bind-
ing and entry into liver cells are nearly as effective as those of
AAV8 (Thomas et al., 2004). Given our observation that the
Y-to-F mutations did not enhance AAV8 and AAV9 in liver,
muscle, and heart, we suspect that intracellular trafficking, in
particular the escape of proteasomal degradation, may not be
the rate-limiting step for these two vectors in the above-cited
tissues. Other steps, instead, such as cell surface receptor
distribution in different cell types and tissues, may be more
critical. In fact, the discovery of the AAV9 primary receptor,
terminal N-linked galactose, strongly supports this scenario
(Bell et al., 2011; Shen et al., 2011). These authors showed that
treatment of tissues, for example, the airway, with recom-
binant sialidase to expose more terminal N-linked galactose
residues dramatically enhanced AAV9 gene transfer to air-
way cells. On the other hand, the primary receptor for AAV2
is heparan sulfate proteoglycan (Summerford and Samulski,
1998), which is universally distributed in nearly all cell types
but with variable abundance. It was observed that AAV2
preferentially infected skeletal muscle slow-twitch myofi-
bers, which display more abundant heparin molecules
(Pruchnic et al., 2000). It remains elusive why AAV6 Y-to-F
mutants were more effective in tibialis anterior muscle than
in gastrocnemius muscle by intramuscular injection, and
why they showed no effects by systemic administration
(Qiao et al., 2010).
Another possibility is that simultaneous ablations of
multiple tyrosine residues are required in order to achieve
significant enhancement of gene transfer by AAV8 and
AAV9 vectors in muscle and heart. Although a single Y-to-F
mutation enhanced AAV2 gene transfer by more than 1 log,
triple mutation enhanced gene transfer efficiencies even
more (Markusic et al., 2011) in intro and also in the eye, liver,
and muscle ( Jayandharan et al., 2011). One report showed
that a double mutation of Y446F and Y731F enhanced AAV9
gene transfer in the retina and brain after systemic injection
into neonatal mice, but without mentioning other tissues
(Dalkara et al., 2011). The results suggested that ubiquitina-
tion and viral particle degradation could be a rate-limiting
step for AAV9-mediated gene transfer in the retina. How-
ever, it remains to be investigated whether it holds true in
muscle, heart, and liver.
Finally, our negative finding of AAV8 and AAV9 mutants
in mouse skeletal muscle and heart is also in stark contrast to
the results of one report (Zhang et al., 2009), despite the fact
that both laboratories used the same mutants provided by
the Srivastava laboratory. However, Zhang and colleagues
observed multiple fold enhancement by the mutants, espe-
cially the AAV9-Y731F mutant, which rendered more than
10-fold enhancement over the wild-type AAV9 vector. His-
tochemical staining of the reporter alkaline phosphatase gene
expression in thin sections of muscle and heart displayed
even more dramatic enhancement. To reconcile the large
discrepancy, we have searched for possible factors that may
have contributed to the different results. One possible factor
is the difference in mouse strains. In our experiments we
initially used outbred ICR mice instead of C57BL/6 mice.
However, when we repeated our experiments in adult
C57BL/6 mice, no enhancement by the mutant AAV8 and
AAV9 vectors was observed either (Figs. 4 and 5), ruling out
mouse strain as a contributing factor. A second possible
factor is the difference in reporter genes, that is, luciferase
and LacZ versus human placenta alkaline phosphatase. We
obtained essentially consistent results using both luciferase
and LacZ reporter genes. The luciferase assay is well known
for its low background whereas our LacZ has a nucleus lo-
calization signal, which displays nuclear staining that was
FIG. 6. Direct intramuscular injection of mutant and wild-
type AAV8 and AAV9 vectors encoding luciferase into adult
ICR mice. For each ICR mouse, two injection sites positioned
in the middle belly of the tibialis anterior (TA) and gastroc-
nemius (Gas) muscles received AAV vector at a dose of
3 · 1010 VG in a 50-ll volume per site. Luciferase activities in
the injected muscles were measured 3 weeks later and no
significant difference was found ( p > 0.05 for all comparisons
by one-way ANOVA, n = 3). (a) Luciferase expression me-
diated by wild-type and mutant AAV8 vectors. (b) Lucifer-
ase expression mediated by wild-type and mutant AAV9
vectors.
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clearly shown in the tissue thin-section X-Gal staining (Fig.
3a). In skeletal muscle cells with their large cytoplasm, in-
complete translation of LacZ to the nucleus could be seen,
which was not due to background staining. By contrast, endo-
genous alkaline phosphatase activities are high in mouse
tissues, which require heat inactivation to bleach the high
background. If the process somehow failed, high back-
ground staining would occur. Other factors including incor-
rect vector titers, dilutions, and inconsistent vector potency
from batch to batch would also contribute to inconsistent
results. Although the precise reason(s) remain to be further
investigated, we believe that it is informative to publish a
negative finding so that other researchers will take it into
consideration when designing and choosing vectors, in order
to minimize unnecessary duplicated efforts and expense.
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